DK2805723T3 - Cladribin-regime til behandling af multipel sclerose - Google Patents
Cladribin-regime til behandling af multipel scleroseInfo
- Publication number
- DK2805723T3 DK2805723T3 DK14001970.4T DK14001970T DK2805723T3 DK 2805723 T3 DK2805723 T3 DK 2805723T3 DK 14001970 T DK14001970 T DK 14001970T DK 2805723 T3 DK2805723 T3 DK 2805723T3
- Authority
- DK
- Denmark
- Prior art keywords
- multiple sclerosis
- treatment
- cladribine
- regimen
- cladribine regimen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63866904P | 2004-12-22 | 2004-12-22 | |
EP04106909 | 2004-12-22 | ||
EP10182676.6A EP2263678B1 (en) | 2004-12-22 | 2005-12-20 | Cladribine regimen for treating early secondary progressive Multiple Sclerosis |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2805723T3 true DK2805723T3 (da) | 2018-01-29 |
Family
ID=36227798
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14001970.4T DK2805723T3 (da) | 2004-12-22 | 2005-12-20 | Cladribin-regime til behandling af multipel sclerose |
DK18151634.5T DK3332789T3 (da) | 2004-12-22 | 2005-12-20 | Cladribinkur til behandling af multipel sklerose |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18151634.5T DK3332789T3 (da) | 2004-12-22 | 2005-12-20 | Cladribinkur til behandling af multipel sklerose |
Country Status (24)
Country | Link |
---|---|
US (2) | US7713947B2 (da) |
EP (6) | EP2275110B1 (da) |
JP (7) | JP5795456B2 (da) |
KR (1) | KR20070091662A (da) |
AR (1) | AR052830A1 (da) |
AU (2) | AU2005318190B2 (da) |
BR (1) | BRPI0517132B8 (da) |
CA (2) | CA3087419C (da) |
CY (3) | CY1112614T1 (da) |
DK (2) | DK2805723T3 (da) |
EA (1) | EA015799B1 (da) |
ES (1) | ES2921858T3 (da) |
FR (1) | FR18C1008I2 (da) |
HR (1) | HRP20120228T1 (da) |
HU (2) | HUE059133T2 (da) |
IL (2) | IL183930A0 (da) |
LT (2) | LT3332789T (da) |
LU (1) | LUC00064I2 (da) |
MX (1) | MX2007007610A (da) |
NO (1) | NO20073813L (da) |
PL (3) | PL1827461T3 (da) |
SG (1) | SG160391A1 (da) |
SI (2) | SI2805723T1 (da) |
WO (1) | WO2006067141A1 (da) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2649810A1 (en) | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
EP2343074A1 (en) | 2009-12-23 | 2011-07-13 | Merck Serono S.A. | Use of purine analogues for treating airway diseases |
WO2011117267A1 (en) | 2010-03-24 | 2011-09-29 | Merck Serono Sa | Cladribine treatment of multiple sclerosis in patient groups defined by genotype |
EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
WO2012097867A1 (en) | 2011-01-18 | 2012-07-26 | Synthon Bv | Cladribine particles and pharmaceutical compositions comprising them |
GB201401465D0 (en) * | 2014-01-29 | 2014-03-12 | Roach Arthur H | Use of cladribine for treating autoimmune inflammatory disease |
GB2564717A (en) | 2017-07-21 | 2019-01-23 | Chord Therapeutics S A R L | Use of cladribine for treating autoimmune neuromuscular disease |
JP2021504363A (ja) | 2017-11-24 | 2021-02-15 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 進行型多発性硬化症の処置における使用のためのクラドリビン処方計画 |
GB2601786A (en) | 2020-12-10 | 2022-06-15 | Chord Therapeutics S A R L | Use of cladribine for treating immune brain disease |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1269659A (en) | 1984-08-06 | 1990-05-29 | Brigham Young University | Method for the production of 2'-deoxyadenosine compounds |
US5310732A (en) | 1986-02-03 | 1994-05-10 | The Scripps Research Institute | 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis |
US4964848A (en) * | 1988-06-27 | 1990-10-23 | Bloom Philip M | Treatment of multiple sclerosis with lymphocytapheresis and chemo-immunosuppression |
US5208327A (en) | 1991-12-18 | 1993-05-04 | Ortho Pharmaceutical Corporation | Intermediates useful in a synthesis of 2-chloro-2'-deoxyadenosine |
US5641757A (en) | 1994-12-21 | 1997-06-24 | Ortho Pharmaceutical Corporation | Stable 2-chloro-2'-deoxyadenosine formulations |
PL321431A1 (en) | 1994-12-22 | 1997-12-08 | Ortho Pharma Corp | Soluble 2-chloro-2'deoxyadenosine compositions |
US6194395B1 (en) | 1999-02-25 | 2001-02-27 | Orthro-Mcneil Pharmaceutical, Inc. | Cyclodextrin cladribine formulations |
WO2000064918A1 (en) | 1999-04-28 | 2000-11-02 | Sterrenbeld Biotechnologie North America, Inc. | METHOD FOR THE PRODUCTION OF 2-CHLORO-2'-DEOXYADENOSINE (CLADRIBINE) AND ITS 3,5-DI-O-p-TOLUOYL DERIVATIVE |
DE10237146A1 (de) * | 2002-08-13 | 2004-03-04 | Medac Gesellschaft für klinische Spezialpräparate mbH | Verwendung von Treosulfan und Derivaten davon zur Behandlung der Multiplen Sklerose |
US7572909B2 (en) | 2002-09-25 | 2009-08-11 | Brigham Young University | Method for the preparation of 2-halo-2′-deoxyadenosine compounds from 2′-deoxyguanosine |
GB2394658A (en) * | 2002-11-01 | 2004-05-05 | Cancer Rec Tech Ltd | Oral anti-cancer composition |
CN1761471A (zh) * | 2003-02-25 | 2006-04-19 | 应用研究系统Ars股份公司 | 利巴韦林与干扰素β在脱髓鞘疾病中的联用 |
EA009714B1 (ru) | 2003-03-28 | 2008-02-28 | Арес Трейдинг С.А. | Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки |
RS20050735A (en) | 2003-03-28 | 2008-06-05 | Ares Trading S.A., | Cladribine formulations for improved oral and transmucosal delivery |
CA2649810A1 (en) * | 2006-05-24 | 2007-11-29 | Laboratoires Serono S.A. | Cladribine regimen for treating multiple sclerosis |
-
2005
- 2005-12-20 EP EP10182632.9A patent/EP2275110B1/en active Active
- 2005-12-20 LT LTEP18151634.5T patent/LT3332789T/lt unknown
- 2005-12-20 SG SG201001736-6A patent/SG160391A1/en unknown
- 2005-12-20 CA CA3087419A patent/CA3087419C/en active Active
- 2005-12-20 EP EP10182676.6A patent/EP2263678B1/en active Active
- 2005-12-20 DK DK14001970.4T patent/DK2805723T3/da active
- 2005-12-20 EP EP05823474A patent/EP1827461B1/en active Active
- 2005-12-20 HU HUE18151634A patent/HUE059133T2/hu unknown
- 2005-12-20 MX MX2007007610A patent/MX2007007610A/es unknown
- 2005-12-20 BR BRPI0517132A patent/BRPI0517132B8/pt active IP Right Grant
- 2005-12-20 AU AU2005318190A patent/AU2005318190B2/en active Active
- 2005-12-20 EP EP18151634.5A patent/EP3332789B1/en active Active
- 2005-12-20 PL PL05823474T patent/PL1827461T3/pl unknown
- 2005-12-20 EP EP14001970.4A patent/EP2805723B1/en not_active Revoked
- 2005-12-20 DK DK18151634.5T patent/DK3332789T3/da active
- 2005-12-20 SI SI200532191T patent/SI2805723T1/en unknown
- 2005-12-20 PL PL18151634.5T patent/PL3332789T3/pl unknown
- 2005-12-20 ES ES18151634T patent/ES2921858T3/es active Active
- 2005-12-20 EA EA200701221A patent/EA015799B1/ru active Protection Beyond IP Right Term
- 2005-12-20 KR KR1020077016508A patent/KR20070091662A/ko not_active Application Discontinuation
- 2005-12-20 WO PCT/EP2005/056954 patent/WO2006067141A1/en active Application Filing
- 2005-12-20 CA CA2588966A patent/CA2588966C/en active Active
- 2005-12-20 SI SI200532305T patent/SI3332789T1/sl unknown
- 2005-12-20 US US11/722,018 patent/US7713947B2/en active Active
- 2005-12-20 EP EP22166610.0A patent/EP4070800A1/en active Pending
- 2005-12-20 PL PL14001970T patent/PL2805723T3/pl unknown
- 2005-12-20 JP JP2007547486A patent/JP5795456B2/ja active Active
- 2005-12-21 AR ARP050105411A patent/AR052830A1/es not_active Application Discontinuation
-
2007
- 2007-06-14 IL IL183930A patent/IL183930A0/en active IP Right Grant
- 2007-07-20 NO NO20073813A patent/NO20073813L/no not_active Application Discontinuation
-
2010
- 2010-04-23 US US12/766,173 patent/US8377903B2/en active Active
-
2011
- 2011-02-23 AU AU2011200768A patent/AU2011200768B2/en active Active
- 2011-04-17 IL IL212421A patent/IL212421A/en active IP Right Grant
-
2012
- 2012-03-13 HR HR20120228T patent/HRP20120228T1/hr unknown
- 2012-04-11 CY CY20121100358T patent/CY1112614T1/el unknown
-
2013
- 2013-05-30 JP JP2013113850A patent/JP5908863B2/ja active Active
-
2015
- 2015-06-16 JP JP2015120875A patent/JP6092945B2/ja active Active
-
2016
- 2016-04-08 JP JP2016078293A patent/JP6290962B2/ja active Active
-
2017
- 2017-02-09 JP JP2017022375A patent/JP6430554B2/ja active Active
-
2018
- 2018-01-18 CY CY20181100065T patent/CY1119790T1/el unknown
- 2018-02-12 LU LU00064C patent/LUC00064I2/fr unknown
- 2018-02-14 FR FR18C1008C patent/FR18C1008I2/fr active Active
- 2018-02-15 HU HUS1800009C patent/HUS1800009I1/hu unknown
- 2018-02-20 LT LTPA2018503C patent/LTC2805723I2/lt unknown
- 2018-02-28 CY CY2018006C patent/CY2018006I1/el unknown
- 2018-07-09 JP JP2018129918A patent/JP2018165271A/ja active Pending
-
2020
- 2020-08-06 JP JP2020134010A patent/JP2020193206A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2805723T3 (da) | Cladribin-regime til behandling af multipel sclerose | |
WO2009085990A3 (en) | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
IL177283A (en) | Pyrazolopyrimidine compounds, their use in the preparation of medicines and pharmaceuticals containing them | |
LTC1781298I2 (lt) | Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui | |
WO2009055006A8 (en) | Deuterated darunavir | |
CL2007003100A1 (es) | Compuestos derivados de pirimidina, inhibidores de cisteina proteasa; procesos de preparacion; sales de los compuestos; composicion farmaceutica; y uso para el tratamiento de la malaria. | |
WO2007146248A3 (en) | Stable laquinimod preparations | |
CL2012001133A1 (es) | Composicion farmaceutica oral que comprende ponatinib 3-(imidazo[1,2-b]piridazin-3-iletinil)-4-metil-n-(4-((4-metilpiperazin-1-il)-metil)-3-(trifluorometil)fenil)benzamida y al menos un excipiente farmaceuticamente aceptable; y su uso para el tratamiento de neoplasma, cancer o un trastorno hiperproliferativo. | |
WO2012004706A3 (en) | Chemical compounds | |
WO2007038459A3 (en) | Carboxyamine compounds and their use in the treatment of hdac dependent diseases | |
WO2009137391A3 (en) | Benzene sulfonamide thiazole and oxazole compounds | |
WO2011113060A3 (en) | Antiviral compounds and methods of use thereof | |
WO2012046030A3 (en) | Phosphodiesterase inhibitors | |
CL2007001838A1 (es) | Compuestos derivados de 4-oxoquinolina; composicion farmaceutica; y uso del compuesto para la produccion de un agente anti-vih. | |
WO2009081174A3 (en) | Anti - retroviral combination | |
WO2005123049A3 (en) | A pharmaceutical composition for increasing the mitochondrial genesis | |
WO2008129501A3 (en) | Pharmaceutical compositions of duloxetine | |
ITFI20050041A1 (it) | Idrossammati come inibitori dell'istone deacelitasi, loro preparazione e formulazioni farmaceutiche che li contengono | |
WO2008073863A3 (en) | Preparation and utility of substituted allylamines | |
NO20065898L (no) | 1-heterocyklyl-1,5-dihydro-pyrido[3,2-b]indol-2-oner | |
WO2008004100A3 (en) | Therapeutic compounds | |
BRPI0618370A2 (pt) | formulação aerossol de medicamento, uso do mesmo e kit de inalação | |
WO2006055663A3 (en) | The use of novel antibacterial compounds | |
WO2005107717A8 (en) | Oral dosage form for the extended release of biguanide and sulfonylurea | |
WO2007066200A3 (en) | Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications |